<p>AbbVie (纽约证券交易所：ABBV - 获取免费报告) 在周四公布了其财报。据 Briefing.com 报道，该公司本季度每股收益（EPS）为 2.65 美元，超过了预期的 2.57 美元，超出 0.08 美元。AbbVie 的净利润率为 11.02%，净资产收益率为 179.47%。本季度该公司的营收为 144.6 亿美元，高于分析师预期的 140.2 亿美元。与去年同期相比，公司每股收益为 2.91 美元。本季度公司的营收同比增长了 4.3%。AbbVie 将其 2024 财年指导范围更新为每股 10.71-10.91 美元。</p>
<h2>AbbVie 股价上涨 1.7%</h2>
<ul>
<li>Teva 制药股票：挖掘这家仿制药宝石的价值</li>
</ul>
<p>纽约证券交易所 ABBV 周五上涨 3.07 美元，收于 185.24 美元。该股交易量为 6,948,346 股，高于平均交易量 5,572,868 股。该公司的 50 日移动平均价格为 167.30 美元，200 日移动平均价格为 169.38 美元。该公司的市值为 3,271.1 亿美元，市盈率为 55.39，PEG 比率为 2.23，β系数为 0.64。AbbVie 的 52 周最低价为 135.85 美元，52 周最高价为 186.85 美元。该公司的速动比率为 0.83，流动比率为 0.94，负债资产比率为 7.93。</p>
<h2>AbbVie 股息宣布</h2>
<p>该公司最近宣布了季度股息，将于 8 月 15 日（周四）支付。7 月 15 日（周一）持股的投资者将获得 1.55 美元的股息。该股息的除息日为 7 月 15 日（周一）。这代表年化基础上的 6.20 美元股息和 3.35% 的收益率。AbbVie 的股息支付比率（DPR）目前为 183.98%。</p>
<h2>分析师评级变动</h2>
<ul>
<li>MarketBeat 周评 - 7/1 - 7/5</li>
</ul>
<p>一些分析师最近对 ABBV 股票发表了评论。Piper Sandler Companies 在 7 月 3 日星期三的研究报告中重申了对 AbbVie 股票的 “超配” 评级，并设定了 190.00 美元的目标价。富国银行公司将 AbbVie 股票的目标价从 200.00 美元上调至 205.00 美元，并在周五的研究报告中给予该公司 “超配” 评级。Cantor Fitzgerald 重申了对 AbbVie 股票的 “超配” 评级，并在周五的报告中将目标价定为 200.00 美元。摩根士丹利将 AbbVie 的目标价从 191.00 美元上调至 196.00 美元，并在 7 月 11 日星期四的研究报告中给予该股票 “超配” 评级。最后，巴克莱将 AbbVie 的目标价从 187.00 美元上调至 200.00 美元，并在周五的研究报告中给予该公司 “超配” 评级。两家分析公司对该股票给予持有评级，十三家给予买入评级，一家给予强烈买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “中等买入”，共识目标价为 188.71 美元。</p>
<p><strong>获取我们关于 ABBV 的最新研究报告</strong></p>
<h2>内部人员活动</h2>
<ul>
<li>AbbVie 股票：投资者购买的完美时机</li>
</ul>
<p>相关消息称，董事长 Richard A. Gonzalez 于 7 月 17 日（周三）以 175.00 美元的平均价格出售了公司股票的 282,845 股。交易完成后，董事长直接持有公司股票 513,099 股，价值 89,792,325 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接获得。公司内部人员持有公司股票的比例为 0.25%。</p>
<h2>关于 AbbVie（获取免费报告）</h2>
<p>AbbVie Inc 在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，用于自身免疫性和肠道 Behçet 病以及脓疱病；Skyrizi 用于治疗中度至重度斑块状银屑病、银屑病和克罗恩病；Rinvoq 用于治疗类风湿和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴突型脊柱关节病、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血液癌症患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血液癌症。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票</li>
<li>最波动性股票，投资者需要了解的事项</li>
<li>3M 惊喜和复苏加速：现在投资还不算太晚</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>斯凯奇股票在消费者自由选择领域表现强劲</li>
<li>投资旅游股带来的好处</li>
<li>科技股下跌，这些股票提供购买机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ Nvidia 内部人士抛售股票（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2"/></p>
<h2>现在是否值得投资 1,000 美元购买 AbbVie 股票？</h2>
<p>在考虑 AbbVie 之前，您可能想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 AbbVie 并不在名单上。</p>
<p>尽管 AbbVie 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

艾伯维

<p>AbbVie（纽约证券交易所：ABBV）发布了季度收益结果，超过了共识预期，并报告营收增长了 4.3%。该公司还更新了 2024 财年的指引。AbbVie 的股价在公告后上涨了 1.7%。分析师们给予该股票 “中等买入” 评级，共识目标价为 188.71 美元。董事长 Richard A. Gonzalez 出售了公司股票超过 28 万股。AbbVie 是一家在全球开发和销售药品的制药公司</p>

<p>AbbVie (NYSE:ABBV - Get Free Report) posted its earnings results on Thursday. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.08, Briefing.com reports. AbbVie had a net margin of 11.02% and a return on equity of 179.47%. The business had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.02 billion. During the same period in the prior year, the company posted $2.91 EPS. The company's revenue for the quarter was up 4.3% on a year-over-year basis. AbbVie updated its FY24 guidance to $10.71-10.91 EPS.</p>
<div class="lb-trans"><p>AbbVie (纽约证券交易所：ABBV - 获取免费报告) 在周四公布了其财报。据 Briefing.com 报道，该公司本季度每股收益（EPS）为 2.65 美元，超过了预期的 2.57 美元，超出 0.08 美元。AbbVie 的净利润率为 11.02%，净资产收益率为 179.47%。本季度该公司的营收为 144.6 亿美元，高于分析师预期的 140.2 亿美元。与去年同期相比，公司每股收益为 2.91 美元。本季度公司的营收同比增长了 4.3%。AbbVie 将其 2024 财年指导范围更新为每股 10.71-10.91 美元。</p>
</div><h2>AbbVie Stock Up 1.7 %</h2>
<ul>
<li>Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem</li>
</ul>
<div class="lb-trans"><h2>AbbVie 股价上涨 1.7%</h2>
<ul>
<li>Teva 制药股票：挖掘这家仿制药宝石的价值</li>
</ul>
</div><p>NYSE ABBV traded up $3.07 on Friday, hitting $185.24. 6,948,346 shares of the stock were exchanged, compared to its average volume of 5,572,868. The company has a 50-day moving average price of $167.30 and a 200-day moving average price of $169.38. The company has a market cap of $327.11 billion, a PE ratio of 55.39, a PEG ratio of 2.23 and a beta of 0.64. AbbVie has a fifty-two week low of $135.85 and a fifty-two week high of $186.85. The company has a quick ratio of 0.83, a current ratio of 0.94 and a debt-to-equity ratio of 7.93.</p>
<div class="lb-trans"><p>纽约证券交易所 ABBV 周五上涨 3.07 美元，收于 185.24 美元。该股交易量为 6,948,346 股，高于平均交易量 5,572,868 股。该公司的 50 日移动平均价格为 167.30 美元，200 日移动平均价格为 169.38 美元。该公司的市值为 3,271.1 亿美元，市盈率为 55.39，PEG 比率为 2.23，β系数为 0.64。AbbVie 的 52 周最低价为 135.85 美元，52 周最高价为 186.85 美元。该公司的速动比率为 0.83，流动比率为 0.94，负债资产比率为 7.93。</p>
</div><h2>AbbVie Dividend Announcement</h2>
<div class="lb-trans"><h2>AbbVie 股息宣布</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Monday, July 15th will be issued a $1.55 dividend. The ex-dividend date of this dividend is Monday, July 15th. This represents a $6.20 dividend on an annualized basis and a yield of 3.35%. AbbVie's dividend payout ratio (DPR) is presently 183.98%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 8 月 15 日（周四）支付。7 月 15 日（周一）持股的投资者将获得 1.55 美元的股息。该股息的除息日为 7 月 15 日（周一）。这代表年化基础上的 6.20 美元股息和 3.35% 的收益率。AbbVie 的股息支付比率（DPR）目前为 183.98%。</p>
</div><h2>Analyst Ratings Changes</h2>
<ul>
<li>MarketBeat Week in Review – 7/1 - 7/5</li>
</ul>
<div class="lb-trans"><h2>分析师评级变动</h2>
<ul>
<li>MarketBeat 周评 - 7/1 - 7/5</li>
</ul>
</div><p>A number of analysts have recently commented on ABBV shares. Piper Sandler Companies reissued an &#34;overweight&#34; rating and set a $190.00 target price on shares of AbbVie in a research note on Wednesday, July 3rd. Wells Fargo &amp; Company increased their price target on shares of AbbVie from $200.00 to $205.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating and issued a $200.00 price objective on shares of AbbVie in a report on Friday. Morgan Stanley increased their price objective on AbbVie from $191.00 to $196.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, July 11th. Finally, Barclays lifted their target price on AbbVie from $187.00 to $200.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $188.71.</p>
<div class="lb-trans"><p>一些分析师最近对 ABBV 股票发表了评论。Piper Sandler Companies 在 7 月 3 日星期三的研究报告中重申了对 AbbVie 股票的 “超配” 评级，并设定了 190.00 美元的目标价。富国银行公司将 AbbVie 股票的目标价从 200.00 美元上调至 205.00 美元，并在周五的研究报告中给予该公司 “超配” 评级。Cantor Fitzgerald 重申了对 AbbVie 股票的 “超配” 评级，并在周五的报告中将目标价定为 200.00 美元。摩根士丹利将 AbbVie 的目标价从 191.00 美元上调至 196.00 美元，并在 7 月 11 日星期四的研究报告中给予该股票 “超配” 评级。最后，巴克莱将 AbbVie 的目标价从 187.00 美元上调至 200.00 美元，并在周五的研究报告中给予该公司 “超配” 评级。两家分析公司对该股票给予持有评级，十三家给予买入评级，一家给予强烈买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “中等买入”，共识目标价为 188.71 美元。</p>
</div><p><strong>Get Our Latest Research Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 ABBV 的最新研究报告</strong></p>
</div><h2>Insider Activity</h2>
<ul>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
</ul>
<div class="lb-trans"><h2>内部人员活动</h2>
<ul>
<li>AbbVie 股票：投资者购买的完美时机</li>
</ul>
</div><p>In related news, Chairman Richard A. Gonzalez sold 282,845 shares of the business's stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $175.00, for a total value of $49,497,875.00. Following the completion of the sale, the chairman now directly owns 513,099 shares of the company's stock, valued at $89,792,325. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.25% of the company's stock.</p>
<div class="lb-trans"><p>相关消息称，董事长 Richard A. Gonzalez 于 7 月 17 日（周三）以 175.00 美元的平均价格出售了公司股票的 282,845 股。交易完成后，董事长直接持有公司股票 513,099 股，价值 89,792,325 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接获得。公司内部人员持有公司股票的比例为 0.25%。</p>
</div><h2>About AbbVie (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 AbbVie（获取免费报告）</h2>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>AbbVie Inc 在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，用于自身免疫性和肠道 Behçet 病以及脓疱病；Skyrizi 用于治疗中度至重度斑块状银屑病、银屑病和克罗恩病；Rinvoq 用于治疗类风湿和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴突型脊柱关节病、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血液癌症患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血液癌症。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than AbbVie</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Skechers Stock Shows Strength Among Consumer Discretionary Sector</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Tech Stocks Tumble, These Stocks Present Buying Opportunity</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票</li>
<li>最波动性股票，投资者需要了解的事项</li>
<li>3M 惊喜和复苏加速：现在投资还不算太晚</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>斯凯奇股票在消费者自由选择领域表现强劲</li>
<li>投资旅游股带来的好处</li>
<li>科技股下跌，这些股票提供购买机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Nvidia insiders dumping shares (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ Nvidia 内部人士抛售股票（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8736&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in AbbVie right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买 AbbVie 股票？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 AbbVie 之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 AbbVie 并不在名单上。</p>
</div><p>While AbbVie currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 AbbVie 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

艾伯维（NYSE:ABBV）发布财报结果